U.S., April 9 -- ClinicalTrials.gov registry received information related to the study (NCT06916585) titled 'A Phase II Trail of AS1501' on March 31.
Brief Summary: **Document Name: This Trial is a Phase II Clinical Study.docx** **Document Content:**
* This trial is a Phase II clinical study, conducted in two stages:
* **Phase IIa:** A sentinel, single-arm design will be employed. A total of 12 early ACLF subjects are expected to be enrolled in the 0.5 mg/kg dose group. The first 2 subjects will serve as sentinels and be enrolled sequentially to receive a single intravenous dose. If no drug-related SAEs (Serious Adverse Events) occur in these 2 sentinel subjects within 2 weeks after the first dose, the remaining 10 subjects will be enrol...